지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 88 - 97 (10page)
이용수
초록· 키워드
오류제보하기
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the inci- dence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carci- noma patients treated with gefitinib.
Materials and Methods A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients’ medical records were reviewed independently by inves- tigators to identify the causes of pulmonary toxicities.
Results Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (! 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71).
Conclusion The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a life- threatening adverse effect of gefitinib, and the development of ILD was significantly asso- ciated with a lower baseline serum albumin level.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Cohen MH / 2003 / FDA drug approval summary : gefitinib(ZD1839)(Iressa)tablets / Oncologist 8:303~306
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
Maemondo M / 2010 / Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR / N Engl J Med 362:2380~2388
Inoue A / 2003 / Severe acute interstitial pneumonia and gefitinib / Lancet 361:137~139
Min JH / 2011 / Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight / Cancer Chemother Pharmacol 68:1099~1109
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
Maemondo M / 2010 / Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR / N Engl J Med 362:2380~2388
Inoue A / 2003 / Severe acute interstitial pneumonia and gefitinib / Lancet 361:137~139
Min JH / 2011 / Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight / Cancer Chemother Pharmacol 68:1099~1109
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease
Tuberculosis and Respiratory Diseases
2019 .01
-
Recent Advances in Basic and Clinical Aspects of Rheumatoid Arthritis-associated Interstitial Lung Diseases
대한류마티스학회지
2022 .04
-
간질성 폐질환의 진단 및 치료: 특발성 폐섬유증을 중심으로 알아보기
대한의사협회지
2020 .01
-
Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Cancer Research and Treatment
2018 .01
-
Clinico-pathological Analysis of the Lungs from Patients with Lung Transplantation in a Single Institute in Korea
Journal of Korean Medical Science
2015 .01
-
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction
Tuberculosis and Respiratory Diseases
2019 .01
-
류마티스관절염에 동반된 폐침범의 양상과 관련인자 분석
대한류마티스학회지
2016 .01
-
Pediatric Case Report on an Interstitial Lung Disease with a Novel Mutation of SFTPC Successfully Treated with Lung Transplantation
Journal of Korean Medical Science
2018 .01
-
자가면역 관련 사이질폐질환 치료의 최신지견
대한의사협회지
2021 .01
-
Neutrophil-to-lymphocyte Ratio in Diagnosis of Systemic Sclerosis for Prediction of Interstitial Lung Disease
대한류마티스학회지
2017 .01
-
Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer
Annals of Laboratory Medicine
2017 .01
-
Assessing the Needs for a Pulmonary Rehabilitation Mobile App in Patients with Interstitial Lung Disease: A Mixed Methods Study
성인간호학회 학술대회
2024 .07
-
Association of Serum Biomarkers With Pulmonary Involvement of Rheumatoid Arthritis Interstitial Lung Disease: From KORAIL Cohort Baseline Data
대한류마티스학회지
2021 .10
-
Therapeutic efficacy of tofacitinib in interstitial lung disease model
한국실험동물학회 학술발표대회 논문집
2020 .07
-
The effects of direct hemoperfusion with polymyxin B-immobilized fiber in patients with acute exacerbation of interstitial lung disease
Acute and Critical Care
2021 .01
-
Epidemiology of Rheumatoid Arthritis in Korea
대한류마티스학회지
2021 .01
-
Epidemiology of Lung Cancer in Korea: Recent Trends
Tuberculosis and Respiratory Diseases
2016 .01
-
Risk of Coronavirus Disease Incidence, Severe Presentation, and Mortality in Patients with Lung Cancer
Cancer Research and Treatment
2021 .01
-
Clinical characteristics of juvenile systemic sclerosis in Korea: 31-year single-center study
대한류마티스학회지
2024 .01
-
Risk Factors for Lung Cancer Mortality in a Referral Center
Asian Pacific journal of cancer prevention : APJCP
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0